Citius Oncology reports $5.6M revenue in H1 2026 with strong LYMPHIR launch and $36.5M financing secured

Citius Oncology generated $5.6 million in net revenue for the first half of fiscal 2026 following the December 2025 launch of LYMPHIR, a therapy for CTCL. The company secured up to $36.5 million in debt and equity financing to support commercial expansion and has achieved broad payer coverage with no reimbursement denials. LYMPHIR is now included or under review in 83% of target accounts, with shipments initiated in Europe as well. The company plans to complete its commercial sales team buildout by mid-summer and aims to grow LYMPHIR's market presence both in the U.S. and internationally, supported by positive clinical trial data and strong institutional adoption.